Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zicam Lawsuits Multiply, But Matrixx Is Confident History Will Repeat Itself

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives braces for new lawsuits alleging the firm's Zicam intranasal products cause anosmia - a loss of the sense of smell - following FDA's warning letter to the firm and consumer alert

You may also be interested in...



FDA Adds Homeopathic Enforcement Details, Subtracts Compliance Policy Guide

Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.

FDA 'Evolving' Homeopathic Drug Enforcement With Risk-Based Approach

Problems stated in a draft guidance where FDA will "prioritize enforcement and regulatory actions" includes products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions.

US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach

Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel